品牌分类
品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com
商品描述
Kitsize | 12x8 |
Method | ELISA |
Incubationtime | 3x30min |
Standardrange | cut-offcontrol |
Specimen/Volumes | 10µLserum |
Substrate/isotope | TMB450nm |
RegulatoryStatus: | EU:CE |
Detailsfor: ANAHEp-2ScreenELISA
IBL我们的液体处理专业知识可实现高度复杂的分子诊断技术的可靠自动化,例如细胞遗传学(核型分析和FISH)和分子细胞遗传学(aCGH /阵列比较基因组杂交),其应用范围从代谢疾病和癌症到生殖遗传学和移植药物。该产品组合涵盖了细胞遗传学和分子细胞遗传学工作流程的关键阶段,从标准化工作站,经过验证的应用程序和专用用户界面,到与Tecan Labwerx合作开发的高度定制的平台。 ANA-HEp2ScreenELISAisasolidphaseenzymeimmunoassayforthecombinedqualitativedetectionofIgGantibodiesagainstHEp2cellsinhumanserum.EachwelliscoatedwithlysedHEp2cells.Thetestcollectivelydetects,inonewell,totalANAsagainstdoublestrandedDNA(dsDNA),histones,SS-A(Ro),SS-B(La),Sm,snRNP/Sm,Scl-70,PM-Scl,Jo-1andcentromericantigensalongwithserapositiveforHEp2immunofluorescencetest(IFT).Theassayisatoolinthedifferentialdiagnosisofsystemicrheumaticdiseaseslikesystemiclupuserythematosus(SLE),mixedconnectivetissuediseases(MCTD),scleroderma,Sjögren`ssyndrome,polymyositisanddermatomyositis.Anti-nuclearantibodies(ANA)directedagainstavarietyofnuclearandcytoplasmicantigensoccurinhighfrequencyinsystemicrheumaticdiseasesandthusareanimportanttoolforthedifferentialdiagnosis.Forinstance,SS-A(Ro)andSS-B(La)antibodiesareassociatedwithSLEandSjögren’ssyndrome(SS),anti-dsDNAandanti-SmantibodieswithSLE,anti-histoneantibodieswithSLEanddrug-inducedlupus,anti-RNPantibodieswithmixedconnectivetissuedisease(MCTD)andSLE,anti-Scl-70antibodieswithscleroderma(progressivesystemicsclerosis[PSS]),anti-Jo-1antibodieswithpolymyositisanddermatomyositisandanti-centromereantibodieswithCRESTsyndrome.Indirectimmunofluorescencetest(IFT)oneucaryoticcellslikeHeLaandHEp2hasbeentheestablishedmethodforthedetectionofANAs.AlthoughtheIFTisasensitivetest,itislaboriouswhentestinglargenumbersofpatientsamplesandissubjecttoerrorsfromhumaninterpretationandfromvariABIlityinfluorescentmicroscope.TheELISAtestsystemisanexcellentalternativetotheIFTforscreeningpatient`sserumforthepresenceofANAsofclinicalsignificance.SingleantibodyspecificitieshavetobedeterminedbymorespecifictestingusingELISAsemployingthespecifictargetantigensforasimpleandreliabledifferentiationofANAs.
ForconcretedatapleaseconsulttheInstructionforUseinthedownloadboxontherightside.